1810074-80-6 Usage
Uses
Used in Pharmaceutical Industry:
(R)-2-Amino-3-(4-(trifluoromethoxy)phenyl)propanoic acid hydrochloride is used as a pharmaceutical intermediate for the synthesis of various drugs, leveraging its unique structural features and properties to enhance drug development and discovery.
Used in Medicinal Chemistry:
(R)-2-Amino-3-(4-(trifluoromethoxy)phenyl)propanoic acid hydrochloride is utilized as a chiral building block in medicinal chemistry, enabling the production of enantiomerically pure compounds for improved therapeutic efficacy and reduced side effects.
Used in Drug Discovery:
(R)-2-Amino-3-(4-(trifluoromethoxy)phenyl)propanoic acid hydrochloride is employed in drug discovery processes, serving as a key component in the development of novel pharmaceuticals with potential applications in treating various diseases and medical conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 1810074-80-6 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,8,1,0,0,7 and 4 respectively; the second part has 2 digits, 8 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 1810074-80:
(9*1)+(8*8)+(7*1)+(6*0)+(5*0)+(4*7)+(3*4)+(2*8)+(1*0)=136
136 % 10 = 6
So 1810074-80-6 is a valid CAS Registry Number.
1810074-80-6Relevant academic research and scientific papers
USP30 INHIBITORS
-
Page/Page column 24, (2018/12/13)
The application relates to phenyl- or naphthylsulfonamide derivatives of the structural formula (I). The compounds are described as inhibitors of USP30 (ubiquitin specific peptidase 30) useful for the treatment of conditions involving mitochondrial defects including neurodegenerative diseases such as Alzheimer's and Parkinson's or a neoplastic disease such as leukemia.
SUBSTITUTED PROPANAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME
-
, (2008/06/13)
It is an object of the present invention to provide a substituted propanamide derivative or a pharmacologically acceptable salt thereof that is useful as a prophylactic or therapeutic agent for a bone metabolic disease. The present invention relates to a pharmaceutical composition comprising a compound having General Formula (I) or a pharmacologically acceptable salt thereof as an active ingredient: [wherein, R1 represents a C6-C10 aryl group that may be substituted by a group selected from Substituent Group α, for example; R2 represents a C6-C10aryl group that may be substituted by a group selected from Substituent Group α, for example; and X represents a hydroxyl group or a C1-C6 alkoxy group, for example].
